Graif Assaf, Grilli Christopher J, Scott Amanda L, Patel Keval D, Zimmermann Trelawny J, Wimmer Neil J, Kimbiris George, Leung Daniel A
Department of Vascular and Interventional Radiology, Christiana Care, Newark, DE, USA.
Department of Radiology, Einstein Medical Center Montgomery, East Norriton, PA, USA.
Vasc Endovascular Surg. 2021 Oct;55(7):689-695. doi: 10.1177/15385744211017109. Epub 2021 May 19.
To evaluate the effect of catheter directed thrombolysis (CDT) on heart rate (HR) in patients with sinus tachycardia and acute pulmonary embolism (PE).
A retrospective chart review was performed for patients who underwent CDT with tPA for acute massive or submassive PE between 12/2009 and 2/2020. Included were patients who presented with tachycardia at the time of initiation of CDT. Patients with chronic PE, atrial fibrillation, beta blocker therapy, adjunctive endovascular therapy, systemic thrombolysis, or who expired before conclusion of CDT were excluded. HR was measured approximately every hour during CDT. Graphs were plotted of HR as a function of CDT duration. Two interventional radiologists identified the point of plateau (POP) on the graph where CDT had maximized its benefit in decreasing the patient's HR. Discrepancies were adjudicated by a third interventional radiologist and the median of the 3 measurements was selected. The primary endpoint was the duration of CDT from initiation until the POP.
48 patients were included (52.5 ± 14.7 years, 56.3% female). The POP occurred after 13.1 ± 6.1 hours, by which point HR had been reduced from 110 ± 9.2 bpm to 88 ± 10.6 bpm. Sinus tachycardia was not resolved in 10 patients even though they achieved maximal improvement in HR after 11.3 ± 6.7 hours.
Patients presenting with sinus tachycardia related to acute PE achieved maximal, sustained reduction in heart rate from CDT, after approximately 13 hours of infusion. Patients who did not resolve their tachycardia by that point in time were unlikely to resolve it by the conclusion of CDT.
评估导管直接溶栓(CDT)对窦性心动过速合并急性肺栓塞(PE)患者心率(HR)的影响。
对2009年12月至2020年2月期间接受tPA进行CDT治疗急性大面积或次大面积PE的患者进行回顾性病历审查。纳入在CDT开始时出现心动过速的患者。排除患有慢性PE、心房颤动、β受体阻滞剂治疗、辅助血管内治疗、全身溶栓或在CDT结束前死亡的患者。在CDT期间大约每小时测量一次HR。绘制HR随CDT持续时间变化的图表。两名介入放射科医生确定图表上的平台期点(POP),此时CDT在降低患者HR方面已达到最大益处。差异由第三名介入放射科医生裁决,并选择三次测量的中位数。主要终点是从开始到POP的CDT持续时间。
纳入48例患者(52.5±14.7岁,女性占56.3%)。POP出现在13.1±6.1小时后,此时HR已从110±9.2次/分降至88±10.6次/分。10例患者的窦性心动过速未得到缓解,尽管他们在11.3±6.7小时后HR取得了最大改善。
与急性PE相关的窦性心动过速患者在输注约13小时后,通过CDT实现了心率的最大程度持续降低。到那时仍未缓解心动过速的患者,在CDT结束时也不太可能缓解。